Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 805 results for "novartis ag"

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

European Commission approves new indication for Novartis Lucen...

The European Commission has approved the sixth indication for Novartis Lucentis, making it the only treatment available for a range of choroidal neovascularization (CNV) conditions. Lucentis (ranibizumab) has now been cleared to treat patients for ... Pharmaceutical Business Review, 4 hours ago

76 images for novartis ag

SleekMoney, 3 days ago
Libyan Express, 3 days ago
American Banking News, 1 week ago, 6 days ago, 2 days ago
Business Insider UK, 3 days ago, 3 days ago
SRN News, 4 days ago
Humanosphere, 2 weeks ago
Yahoo! Finance, 2 weeks ago

Study: New cancer drug outperforms chemotherapy

Dec 6 (Reuters) - Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+) advanced ...
 AOL.com1 day ago Cure For Cancer: Novartis Drug Zykadia Beats Chemotherapy In Lung Cancer Patients  International Business Times1 day ago Novartis' drug tops chemotherapy in untreated lung cancer patients  Reuters2 days ago Pfizer blood cancer drug tops standard therapy for untreated patients  Reuters3 days ago
Yahoo! Finance

What Smart Money Has To Say About Novartis AG (ADR) (NVS)

More Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially ...
 Yahoo! Finance2 days ago ABR Of Novartis AG (NYSE:NVS) At 1.91  Markets Daily1 week ago Novartis Stock Is Worth $90 A Share  Seeking Alpha1 week ago Can Novartis AG (NYSE:NVS):Achieve EPS Of $1.0767?  Markets Daily1 week ago
Libyan Express

An experimental treatment eliminated an aggressive blood cancer in 82% of patients treated (NVS)

(Reuters) - An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.
 Business Insider3 days ago Novartis says experimental cancer therapy eliminated blood cancer in 82% of patients  Libyan Express3 days ago New therapy promises cancer cure  Financial Express Bangladesh4 days ago Novartis says 82 pct of leukemia patients in remission after CAR-T  Sharenet4 days ago

Size and vitreomacular attachment of primary full-thickness macular holes

Competing interests EP: travel expenses (Novartis, Bayer, Allergan). EB-S: travel expenses (Bayer). AG: board membership (Alimera, Allergan, Thrombogenics), lectures (Heidelberg, Zeiss) and educational presentations (Novartis, Alcon). RT: board ...
 British Journal of Ophthalmology5 days ago

Novartis Buys Selexys on Favorable Phase II Data on SelG1

Swiss drug maker Novartis AG NVS announced that it has acquired Selexys Pharmaceuticals Corporation, a privately held company specializing in the development of therapeutics for certain hematologic and inflammatory disorders, following the receipt ...
 Yahoo! Finance2 weeks ago
Pharmaceutical Business Review

Novartis AG' $665 Million Bet Pays Off as Selexys Shows Off New Phase II Data

Two weeks ago, Novartis stepped in with a deal to buy Selexys Pharmaceuticals and its Phase III-ready sickle cell disease drug crizanlizumab, an anti-P-selectin antibody designed to slash the number of vaso-occlusive pain crises among patients. New ...
 BioSpace3 days ago Novartis acquires Selexys Pharmaceuticals in $665m deal  Pharmaceutical Business Review2 weeks ago Novartis buys U.S.-based sickle cell drugmaker Selexys  Yahoo! Finance2 weeks ago Novartis AG Scoops Up U.S. Sickle Cell Drugmaker Selexys in $665 Million Deal  BioSpace2 weeks ago

Research and Markets - Biobanking Technologies - Expected to Reach $240.2 Billion in 2021 - Key Vendors are Novartis, Pfizer & Abbott Laboratories

Research and Markets has announced the addition of the "Biobanking: Technologies and Global Markets" report to their offering. The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase ...
 PR Newswire2 days ago PLEURAL EFFUSION GLOBAL CLINICAL TRIALS REVIEW, H2, 2016 - ANALYSIS, TECHNOLOGIES & FORECASTS - VENDORS : Novartis, Biogen, Sanofi - Research and Markets  4 Traders2 weeks ago Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class  Yahoo! Finance13 hours ago Joint Pain Market Review H1, 2016 Growth & Analysis, Trends, Forecasts  Before It's News1 day ago

Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar

Novartis AG 's NVS generic arm, Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology. The study showed that its biosimilar version of Amgen Inc.'s AMGN blockbuster drug, Enbrel, Erelzi, is equivalent ...
 Zacks.com2 weeks ago

Novartis AG the Latest to Join the Asset-Selling Party as it Looks to Offload $496 Million CNS Drugs

Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth. The assets may be ...
 BioSpace1 hour ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less